-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Bronchiolitis -X- _ O
is -X- _ O
a -X- _ O
common -X- _ O
cause -X- _ O
of -X- _ O
hospitalization -X- _ O
among -X- _ O
infants. -X- _ O
The -X- _ O
limited -X- _ O
effectiveness -X- _ O
of -X- _ O
conventional -X- _ O
medication -X- _ O
has -X- _ O
prompted -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
complementary -X- _ B-Intervention
and -X- _ I-Intervention
alternative -X- _ I-Intervention
medicine -X- _ I-Intervention
( -X- _ I-Intervention
CAM -X- _ I-Intervention
) -X- _ I-Intervention
as -X- _ O
alternative -X- _ O
or -X- _ O
adjunctive -X- _ O
therapy -X- _ O
for -X- _ O
the -X- _ O
management -X- _ O
of -X- _ O
bronchiolitis. -X- _ O
AIMS -X- _ O
: -X- _ O
To -X- _ O
determine -X- _ O
the -X- _ O
effectiveness -X- _ O
and -X- _ O
safety -X- _ O
of -X- _ O
CAM -X- _ B-Intervention
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
bronchiolitis -X- _ B-Patient
in -X- _ I-Patient
infants -X- _ I-Patient
aged -X- _ I-Patient
less -X- _ I-Patient
than -X- _ I-Patient
2 -X- _ I-Patient
years. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
A -X- _ O
systematic -X- _ O
electronic -X- _ O
search -X- _ O
was -X- _ O
performed -X- _ O
in -X- _ O
Medline -X- _ O
, -X- _ O
Embase -X- _ O
, -X- _ O
CINAHL -X- _ O
, -X- _ O
AMED -X- _ O
, -X- _ O
and -X- _ O
Cochrane -X- _ O
Central -X- _ O
Register -X- _ O
of -X- _ O
Controlled -X- _ O
Trials -X- _ O
( -X- _ O
CENTRAL -X- _ O
) -X- _ O
from -X- _ O
their -X- _ O
respective -X- _ O
inception -X- _ O
to -X- _ O
June -X- _ O
30 -X- _ O
, -X- _ O
2016 -X- _ O
for -X- _ O
studies -X- _ O
evaluating -X- _ O
CAM -X- _ B-Intervention
as -X- _ O
an -X- _ O
intervention -X- _ O
to -X- _ O
treat -X- _ O
bronchiolitis -X- _ B-Patient
in -X- _ I-Patient
infants -X- _ I-Patient
( -X- _ I-Patient
1 -X- _ I-Patient
month -X- _ I-Patient
to -X- _ I-Patient
2 -X- _ I-Patient
years -X- _ I-Patient
of -X- _ I-Patient
age -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
The -X- _ O
CAM -X- _ O
could -X- _ O
be -X- _ O
any -X- _ O
form -X- _ O
of -X- _ O
treatment -X- _ O
defined -X- _ O
by -X- _ O
the -X- _ O
National -X- _ O
Center -X- _ O
for -X- _ O
Complementary -X- _ O
and -X- _ O
Integrative -X- _ O
Health -X- _ O
( -X- _ O
NCCIH -X- _ O
) -X- _ O
and -X- _ O
was -X- _ O
utilized -X- _ O
either -X- _ O
as -X- _ O
a -X- _ O
single -X- _ O
agent -X- _ O
or -X- _ O
adjunctive -X- _ O
therapy. -X- _ O
The -X- _ O
predefined -X- _ O
primary -X- _ O
outcome -X- _ O
was -X- _ O
length -X- _ O
of -X- _ O
hospital -X- _ O
stay. -X- _ O
Secondary -X- _ O
outcomes -X- _ O
were -X- _ O
time -X- _ O
to -X- _ O
resolution -X- _ O
of -X- _ O
bronchiolitis -X- _ O
symptoms -X- _ O
, -X- _ O
adverse -X- _ O
events -X- _ O
, -X- _ O
and -X- _ O
all -X- _ O
other -X- _ O
clinical -X- _ O
outcomes -X- _ O
reported -X- _ O
by -X- _ O
the -X- _ O
included -X- _ O
studies. -X- _ O
RESULTS -X- _ O
: -X- _ O
The -X- _ O
review -X- _ O
identified -X- _ O
11 -X- _ B-Outcome
studies -X- _ I-Outcome
( -X- _ I-Outcome
8 -X- _ I-Outcome
randomized -X- _ I-Outcome
controlled -X- _ I-Outcome
trials -X- _ I-Outcome
and -X- _ I-Outcome
3 -X- _ I-Outcome
cohort -X- _ I-Outcome
studies -X- _ I-Outcome
) -X- _ I-Outcome
examining -X- _ I-Outcome
four -X- _ I-Outcome
herbal -X- _ I-Outcome
preparations -X- _ I-Outcome
and -X- _ I-Outcome
four -X- _ I-Outcome
supplements -X- _ I-Outcome
used -X- _ I-Outcome
either -X- _ I-Outcome
as -X- _ I-Outcome
adjunctive -X- _ I-Outcome
or -X- _ I-Outcome
alternative -X- _ I-Outcome
therapy -X- _ I-Outcome
for -X- _ I-Outcome
bronchiolitis -X- _ I-Outcome
in -X- _ I-Outcome
904 -X- _ I-Outcome
infants. -X- _ I-Outcome
Most -X- _ I-Outcome
studies -X- _ I-Outcome
were -X- _ I-Outcome
of -X- _ I-Outcome
moderate -X- _ I-Outcome
quality. -X- _ I-Outcome
Among -X- _ I-Outcome
six -X- _ I-Outcome
studies -X- _ I-Outcome
reporting -X- _ I-Outcome
on -X- _ I-Outcome
length -X- _ I-Outcome
of -X- _ I-Outcome
stay -X- _ I-Outcome
, -X- _ I-Outcome
a -X- _ I-Outcome
significant -X- _ I-Outcome
benefit -X- _ I-Outcome
was -X- _ I-Outcome
found -X- _ I-Outcome
for -X- _ I-Outcome
Chinese -X- _ I-Outcome
herbal -X- _ I-Outcome
medicine -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
ribavirin -X- _ I-Outcome
in -X- _ I-Outcome
one -X- _ I-Outcome
cohort -X- _ I-Outcome
study -X- _ I-Outcome
( -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
66 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
vitamin -X- _ I-Outcome
D -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
placebo -X- _ I-Outcome
in -X- _ I-Outcome
one -X- _ I-Outcome
randomized -X- _ I-Outcome
controlled -X- _ I-Outcome
trial -X- _ I-Outcome
( -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
89 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Studies -X- _ I-Outcome
of -X- _ I-Outcome
Chinese -X- _ I-Outcome
herbal -X- _ I-Outcome
medicine -X- _ I-Outcome
( -X- _ I-Outcome
4 -X- _ I-Outcome
studies -X- _ I-Outcome
, -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
365 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
vitamin -X- _ I-Outcome
D -X- _ I-Outcome
( -X- _ I-Outcome
1 -X- _ I-Outcome
study -X- _ I-Outcome
, -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
89 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
N- -X- _ I-Outcome
acetylcysteine -X- _ I-Outcome
( -X- _ I-Outcome
1 -X- _ I-Outcome
study -X- _ I-Outcome
, -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
100 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
magnesium -X- _ I-Outcome
( -X- _ I-Outcome
2 -X- _ I-Outcome
studies -X- _ I-Outcome
, -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
176 -X- _ I-Outcome
) -X- _ I-Outcome
showed -X- _ I-Outcome
some -X- _ I-Outcome
benefits -X- _ I-Outcome
with -X- _ I-Outcome
respect -X- _ I-Outcome
to -X- _ I-Outcome
clinical -X- _ I-Outcome
severity -X- _ I-Outcome
scores -X- _ I-Outcome
, -X- _ I-Outcome
oxygen -X- _ I-Outcome
saturation -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
other -X- _ I-Outcome
symptoms -X- _ I-Outcome
, -X- _ I-Outcome
although -X- _ I-Outcome
data -X- _ I-Outcome
were -X- _ I-Outcome
sparse -X- _ I-Outcome
for -X- _ I-Outcome
any -X- _ I-Outcome
single -X- _ I-Outcome
intervention -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
outcomes -X- _ I-Outcome
assessed -X- _ I-Outcome
and -X- _ I-Outcome
reported -X- _ I-Outcome
varied -X- _ I-Outcome
across -X- _ I-Outcome
studies. -X- _ I-Outcome
Only -X- _ I-Outcome
five -X- _ I-Outcome
studies -X- _ I-Outcome
reported -X- _ I-Outcome
on -X- _ I-Outcome
adverse -X- _ I-Outcome
events -X- _ I-Outcome
; -X- _ I-Outcome
no -X- _ I-Outcome
serious -X- _ I-Outcome
adverse -X- _ I-Outcome
events -X- _ I-Outcome
were -X- _ I-Outcome
reported. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Among -X- _ O
11 -X- _ O
studies -X- _ O
examining -X- _ O
the -X- _ O
effect -X- _ O
of -X- _ O
CAM -X- _ O
on -X- _ O
inpatients -X- _ O
with -X- _ O
bronchiolitis -X- _ O
, -X- _ O
six -X- _ B-Outcome
reported -X- _ I-Outcome
on -X- _ I-Outcome
the -X- _ I-Outcome
reviewâ€™s -X- _ I-Outcome
primary -X- _ I-Outcome
outcome -X- _ I-Outcome
of -X- _ I-Outcome
length -X- _ I-Outcome
of -X- _ I-Outcome
hospital -X- _ I-Outcome
stay. -X- _ I-Outcome
In -X- _ O
general -X- _ O
, -X- _ O
findings -X- _ B-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
show -X- _ I-Outcome
a -X- _ I-Outcome
significant -X- _ I-Outcome
benefit -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
primary -X- _ I-Outcome
outcome. -X- _ I-Outcome
Preliminary -X- _ O
evidence -X- _ O
indicated -X- _ O
that -X- _ O
Chinese -X- _ B-Outcome
herbal -X- _ I-Outcome
medicine -X- _ I-Outcome
mixtures -X- _ I-Outcome
, -X- _ I-Outcome
vitamin -X- _ I-Outcome
D -X- _ I-Outcome
, -X- _ I-Outcome
N-acetylcysteine -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
magnesium -X- _ I-Outcome
might -X- _ I-Outcome
be -X- _ I-Outcome
useful -X- _ I-Outcome
in -X- _ I-Outcome
managing -X- _ I-Outcome
the -X- _ I-Outcome
symptoms -X- _ I-Outcome
of -X- _ I-Outcome
bronchiolitis. -X- _ I-Outcome
However -X- _ O
, -X- _ O
the -X- _ O
evidence -X- _ B-Outcome
was -X- _ I-Outcome
not -X- _ I-Outcome
sufficient -X- _ I-Outcome
or -X- _ O
rigorous -X- _ O
enough -X- _ O
to -X- _ O
formulate -X- _ O
recommendations -X- _ O
for -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
any -X- _ O
CAM. -X- _ O
Among -X- _ O
studies -X- _ O
that -X- _ O
reported -X- _ O
adverse -X- _ O
events -X- _ O
, -X- _ O
no -X- _ O
serious -X- _ O
harms -X- _ O
were -X- _ O
noted -X- _ O
. -X- _ O

